header logo image


Page 369«..1020..368369370371..380390..»

Aro Biotherapeutics Appoints Biotechnology Executive Dr. Christopher Mirabelli to its Board of Directors and Nucleic Acid Therapeutics Expert Dr….

October 13th, 2020 2:59 pm

Aro Biotherapeutics today announced the appointments of Christopher K. Mirabelli, Ph.D., to its Board of Directors and Masad J. Damha, Ph.D., to its Scientific Advisory Board. Drs. Mirabelli and Damha will provide strategic and scientific counsel on the development of novel Centyrin-RNA therapeutic candidates.

"We are excited to welcome Chris, a well-recognized leader in drug development, to our Board of Directors. As the founder of multiple successful biotechnology companies, and an industry veteran with demonstrated experience in the development of new therapies, his insight and guidance will be invaluable as we advance the development of our pipeline of Centyrin-based therapeutic candidates," said Susan Dillon, Ph.D., Co-Founder and Chief Executive Officer of Aro.

Dr. Mirabelli has spent over 35 years in the pharmaceutical and biotechnology industries as a research scientist, senior executive, and venture capital investor. Currently, he is a managing director of the venture capital firm HealthCare Ventures. Dr. Mirabelli is currently Chairman of the Board of Directors of Leap Therapeutics, where he was the Chief Executive Officer from its founding in 2015 until 2020. Previously, Dr. Mirabelli was Chief Executive Officer and Chairman of the Board of Directors of LeukoSite from its founding in 1993 until its acquisition by Millennium Pharmaceuticals in 1999. Dr. Mirabelli was also a Co-Founder of Ionis Pharmaceuticals. He began his industry career in R&D at SmithKline & French Laboratories, and earned his Ph.D. in Molecular Pharmacology from Baylor College of Medicine and his B.S. in Biology from State University of New York (SUNY) at Fredonia.

"I am looking forward to serving on Aros Board of Directors and working with Sue and her team to further advance their proprietary drug-targeting technology," commented Dr. Mirabelli. "The use of antibodies to target drugs to sites of disease in patients has many limitations. Aros novel approach to overcoming these barriers is unique, and Im excited to contribute to the continued development of their pipeline of next-generation biotherapeutic candidates."

Story continues

"We are pleased to have Masad join Aros Scientific Advisory Board. His work in nucleic acid drug discovery and development has been at the forefront of oligonucleotide research, and his scientific insights will be instrumental as we continue to leverage the promise of Centyrins to achieve new therapeutic mechanisms of action," said Karyn ONeil, Ph.D., Co-Founder and Chief Scientific Officer of Aro.

Dr. Damha is a Distinguished James McGill Professor of Chemistry at McGill University. His research group focuses on synthesis and structural analyses of chemically modified oligonucleotides directed toward biomedical and diagnostic applications. His 200+ publications and dozens of issued patents have been widely cited and used in both fundamental sciences and oligonucleotide-based therapeutic applications. Dr. Damha is the recipient of several awards from the Canadian Society for Chemistry, the Queen Elizabeth II Diamond Jubilee Medal (Governor General of Canada), and McGills Fessenden Professorship in Science Innovation. He is currently President of the International Society of Nucleosides, Nucleotides, Nucleic Acids, and he has served as President of the Oligonucleotide Therapeutics Society. Dr. Damha was awarded a Ph.D. in Organic Chemistry and B.Sc. in Chemistry from McGill University.

Dr. Damha commented, "I am very pleased to join Aro Biotherapeutics Scientific Advisory Board and contribute to the development of innovative therapies that enable efficient and specific delivery of nucleic acid conjugates that address important disease targets."

About Aro Biotherapeutics

Aro is a biotechnology company focused on the research and development of a new generation of protein biologics called Centyrins. The company is developing a wholly-owned pipeline of Centyrins and is working with leaders in the industry on leveraging Centyrins for tissue-specific targeting of therapeutics, including nucleic acid drugs for a diverse set of diseases. For more information, visit http://www.arobiotx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201013005040/en/

Contacts

Mike BeyerSam Brown Inc.mikebeyer@sambrown.com 312-961-2502

View original post here:
Aro Biotherapeutics Appoints Biotechnology Executive Dr. Christopher Mirabelli to its Board of Directors and Nucleic Acid Therapeutics Expert Dr....

Read More...

Pharmaceutical & Biotechnology Environmental Monitoring Market Analysis, Growth by Top Companies, Trends by Types and Application, Forecast to…

October 13th, 2020 2:59 pm

Pharmaceutical & Biotechnology Environmental Monitoring Market Analysis, Growth by Top Companies, Trends by Types and Application, Forecast to 2026Published: 11 hours ago Author: Ashwin NaphadeCategory: #news

Advanced report on ' Pharmaceutical & Biotechnology Environmental Monitoring market' Added by Market Study Report, LLC, offers details on current and future growth trends pertaining to the business besides information on myriad regions across the geographical landscape of the ' Pharmaceutical & Biotechnology Environmental Monitoring market'. The report also expands on comprehensive details regarding the supply and demand analysis, participation by major industry players and market share growth statistics of the business sphere.

The latest research report on the Pharmaceutical & Biotechnology Environmental Monitoring market assesses the major factors influencing industry growth with respect to the competitive dynamics and geographical reach. It also ensembles the challenges prevalent in this industry vertical and identifies opportunities that will further aid business expansion. Further, the report revisits all areas of the business to cover the impact of COVID-19 pandemic so as to assist stakeholders in devising new strategies and reinforcing their position in the market.

Request a sample Report of Pharmaceutical & Biotechnology Environmental Monitoring Market at:https://www.marketstudyreport.com/request-a-sample/2947347?utm_source=algosonline.com&utm_medium=Ram

Key pointers from COVID-19 impact analysis:

Important inclusions in the Pharmaceutical & Biotechnology Environmental Monitoring market report:

Ask for Discount on Pharmaceutical & Biotechnology Environmental Monitoring Market Report at:https://www.marketstudyreport.com/check-for-discount/2947347?utm_source=algosonline.com&utm_medium=Ram

Regional scope:

TOC of Pharmaceutical & Biotechnology Environmental Monitoring Market Report Includes:

The Report Answers the key Questions

For More Details On this Report: https://www.marketstudyreport.com/reports/global-pharmaceutical-biotechnology-environmental-monitoring-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

Related Reports:

2. Global Metabolomics Reagents Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)Read More: https://www.marketstudyreport.com/reports/global-metabolomics-reagents-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

Read More Reports On: https://www.marketwatch.com/press-release/air-sampling-pumps-market-size-analysis-share-growth-trends-top-key-players-and-regional-forecast-2025-2020-10-09

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Go here to see the original:
Pharmaceutical & Biotechnology Environmental Monitoring Market Analysis, Growth by Top Companies, Trends by Types and Application, Forecast to...

Read More...

Is Kiniksa Pharmaceuticals Ltd (KNSA) the Top Pick in the Biotechnology Industry? – InvestorsObserver

October 13th, 2020 2:59 pm

The 63 rating InvestorsObserver gives to Kiniksa Pharmaceuticals Ltd (KNSA) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 75 percent of stocks in the Biotechnology industry, KNSAs 63 overall rating means the stock scores better than 63 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 63 would rank higher than 63 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Kiniksa Pharmaceuticals Ltd (KNSA) stock is trading at $21.13 as of 3:25 PM on Monday, Oct 12, an increase of $0.17, or 0.84% from the previous closing price of $20.95. Volume today is 531,806 compared to average volume of 460,930. The stock has traded between $20.21 and $21.24 so far today.

Click Here to get the full Stock Score Report on Kiniksa Pharmaceuticals Ltd (KNSA) Stock.

Visit link:
Is Kiniksa Pharmaceuticals Ltd (KNSA) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Read More...

Is Turning Point Therapeutics Inc (TPTX) the Top Pick in the Biotechnology Industry? – InvestorsObserver

October 13th, 2020 2:59 pm

Turning Point Therapeutics Inc (TPTX) is near the top in its industry group according to InvestorsObserver. TPTX gets an overall rating of 64. That means it scores higher than 64 percent of stocks. Turning Point Therapeutics Inc gets a 78 rank in the Biotechnology industry. Biotechnology is number 27 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 64 would rank higher than 64 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Turning Point Therapeutics Inc (TPTX) stock is trading at $121.08 as of 11:51 AM on Monday, Oct 12, a gain of $9.27, or 8.29% from the previous closing price of $111.81. The stock has traded between $113.22 and $121.91 so far today. Volume today is 388,776 compared to average volume of 403,050.

Click Here to get the full Stock Score Report on Turning Point Therapeutics Inc (TPTX) Stock.

Read the original here:
Is Turning Point Therapeutics Inc (TPTX) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Read More...

Is CEL-SCI Corporation (CVM) The Right Choice in Biotechnology? – InvestorsObserver

October 13th, 2020 2:59 pm

A rating of 24 puts CEL-SCI Corporation (CVM) near the bottom of the Biotechnology industry according to InvestorsObserver. CEL-SCI Corporation's score of 24 means it scores higher than 24% of stocks in the industry. CEL-SCI Corporation also received an overall rating of 36, putting it above 36% of all stocks. Biotechnology is ranked 27 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 36 means the stock is more attractive than 36 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

CEL-SCI Corporation (CVM) stock is trading at $14.94 as of 3:23 PM on Monday, Oct 12, a rise of $0.07, or 0.47% from the previous closing price of $14.87. Volume today is less active than usual. So far 366,839 shares have traded compared to average volume of 545,816 shares. The stock has traded between $14.20 and $15.23 so far today.

Click Here to get the full Stock Score Report on CEL-SCI Corporation (CVM) Stock.

Follow this link:
Is CEL-SCI Corporation (CVM) The Right Choice in Biotechnology? - InvestorsObserver

Read More...

Study On Pharmaceutical and Biotechnology Machines Market (impact of COVID-19) 2020-2026: Air Liquide, Linde Healthcare, Praxair, Air Products -…

October 13th, 2020 2:59 pm

The research report on the global Pharmaceutical and Biotechnology Machines Market outlines Pharmaceutical and Biotechnology Machines market size, value chain structure, regional assessment, industrial environment, and forecast between 2020 to 2026. The rapidly averting industry scenario and current as well as future evaluation of the world Pharmaceutical and Biotechnology Machines market also reported in this study. The report on the global Pharmaceutical and Biotechnology Machines market has been characterized into topological regions, product types, application and prime vendors. Moreover, it delivers different investment opportunities and possible threats based on the intelligent analysis.

NOTE: Our reports include the analysis of the impact of COVID-19 on this industry. Our new sample is updated which correspond in new report showing impact of Covid-19 on Industry trends. Also we are offering 20% discount

Download a sample copy of the Pharmaceutical and Biotechnology Machines market report: https://spiremarketresearch.com/report/global-china-pharmaceutical-biotechnology-machines-market-276133#request-sample

Furthermore, it focuses on the Pharmaceutical and Biotechnology Machines industry trends, distinct growth opportunities key industries, future predictions and Pharmaceutical and Biotechnology Machines industry players. The essential aim of the recent study is to showcase the extremely vital developments of the Pharmaceutical and Biotechnology Machines market across the globe. The research document on the Pharmaceutical and Biotechnology Machines market has been integrated with major insights which will assist the clients to make the perfect business-oriented decisions.

It will help both existing as well as new aspirants to figure out industrial needs, Pharmaceutical and Biotechnology Machines market share, and competitive landscape. The report offers an in-depth analysis about the competitive scenario, Pharmaceutical and Biotechnology Machines industry opportunities, supply as well as demand ratio, different challenges for industry growth and the threats faced by major vendors.

Crucial players involved in this report:

Air LiquideLinde HealthcarePraxairAir ProductsTaiyo Nippon SansoMatheson GasAtlas Copco ABMesser GroupSOL GroupNorcoSicgil India LimitedShenzhen GaofaShenwei MedicalBeijing OrientNanning Lantian

Pharmaceutical and Biotechnology Machines Market fragmentation by product types:

OxygenNitrous OxideMedical AirOthers(Nitrogen, Carbon Dioxide and Helium)

Application covered in this report are:

Hospitals (Labs & Clinics)Home HealthcareUniversities/Research InstitutionsPharmaceutical & Biotechnology Industries

The report on the global Pharmaceutical and Biotechnology Machines market has been fabricated by identifying performance of the respective industry alongside its substantial parameters. The information furnished in the Pharmaceutical and Biotechnology Machines market report is easy to understand so that readers can get detailed statistics about each and every facet in elaborated manner. Different elements including drivers, risks, restraints and opportunities for the Pharmaceutical and Biotechnology Machines market are also explained in brief.

Inquire for this report @: https://spiremarketresearch.com/report/global-china-pharmaceutical-biotechnology-machines-market-276133#inquiry-for-buying

The world Pharmaceutical and Biotechnology Machines market report 2020-2026 is helpful guide for clients along with a large set of customized and systematic data regarding some industrial tactics as it calls for industry-oriented outcomes to offer feasibility studies for clients needs. The global Pharmaceutical and Biotechnology Machines market report has been crafted through qualified and verifiable factors of the Pharmaceutical and Biotechnology Machines market data functioning in the real-time scenarios.

Go here to see the original:
Study On Pharmaceutical and Biotechnology Machines Market (impact of COVID-19) 2020-2026: Air Liquide, Linde Healthcare, Praxair, Air Products -...

Read More...

Nitrome Biosciences Appoints Industry Veteran Perry Karsen as Executive Chairman of the Board of Directors – GlobeNewswire

October 13th, 2020 2:59 pm

SAN FRANCISCO, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Nitrome Biosciences (Nitrome), a privately-held biopharmaceutical company developing a platform around its newly discovered class of enzymes to target Parkinsons disease and many other age-related and inflammation disorders, today announced that it has appointed Perry Karsen, a seasoned leader with 35 years of life sciences experience, as executive chairman of its board of directors.

Perry is a highly respected industry executive with significant expertise in leading and growing successful biopharmaceutical companies, said Irene Griswold-Prenner, Ph.D., founder, chief executive officer and chief scientific officer of Nitrome. Perrys strategic counsel and business acumen will be invaluable to Nitrome as we build out a wholly-owned first-in-class enzyme therapeutics platform based on our novel scientific discoveries.

Perry Karsen was the chief executive officer of Celgene Cellular Therapeutics, a division of Celgene Corporation, from 2013 until his retirement in 2015. Previously, Perry held the position of executive vice president and chief operations officer at Celgene, serving in various management positions, including as senior vice president and head of worldwide business development and president of the Asia/Pacific region. Perry was the president and chief executive officer of Pearl Therapeutics, a biotechnology company subsequently acquired by Astra-Zeneca. In addition, Perry held executive positions at Human Genome Sciences, Bristol-Myers Squibb, Genentech and Abbott Laboratories earlier in his career. He also was a general partner at Pequot Ventures focusing on investments in biotechnology and medical devices. Perry has a Bachelor of Science in biological sciences from the University of Illinois, Urbana, a Master of Arts in teaching biology from Duke University, and an MBA from the Kellogg School of Management at Northwestern University. Perry serves on the board of directors and as chair of several private and public biotechnology companies, and on the board of The Gladstone Foundation. He is also a former member of the board of directors and the executive committee of the Biotechnology Innovation Organization (BIO).

Perry Karsen added, I am very excited to be a part of the Nitrome team and look forward to helping the company realize the vast potential for patients of its enzyme therapeutics platform. Irenes breakthrough discovery could be the key to unraveling degeneration evidenced in many age and inflammation related conditions. The potential for Nitrome to advance science and medicine while impacting patients is profound.

About Nitrome BiosciencesNitrome Biosciences is a platform company developing drugs against a newly identified class of enzymes which play a harmful role in a variety of age and inflammation dependent diseases. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases including Parkinsons, Nitromes lead indication. The company also aims to expand its proprietary platform to include other diseases, such as other neurodegenerative diseases, macular degeneration, heart disease and cancer. Nitrome has been widely recognized and has won multiple awards including the prestigious Target Advancement grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF). For more information, please visit the companys website at http://www.nitromebiosciences.com.

Investor Relations Contact:Alexandra SantosWheelhouse Life Science Advisorsasantos@wheelhouselsa.com

Media Contact:Aljanae Reynolds Wheelhouse Life Science Advisorsareynolds@wheelhouselsa.com

See the original post:
Nitrome Biosciences Appoints Industry Veteran Perry Karsen as Executive Chairman of the Board of Directors - GlobeNewswire

Read More...

Where Does SpringWorks Therapeutics Inc (SWTX) Stock Fall in the Biotechnology Field? – InvestorsObserver

October 13th, 2020 2:59 pm

A rating of 85 puts SpringWorks Therapeutics Inc (SWTX) near the top of the Biotechnology industry according to InvestorsObserver. SpringWorks Therapeutics Inc's score of 85 means it scores higher than 85% of stocks in the industry. SpringWorks Therapeutics Inc also received an overall rating of 69, putting it above 69% of all stocks. Biotechnology is ranked 23 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

SpringWorks Therapeutics Inc (SWTX) stock is trading at $55.01 as of 11:44 AM on Friday, Oct 9, an increase of $3.03, or 5.83% from the previous closing price of $51.98. The stock has traded between $52.79 and $56.45 so far today. Volume today is 339,767 compared to average volume of 364,745.

Click Here to get the full Stock Score Report on SpringWorks Therapeutics Inc (SWTX) Stock.

More:
Where Does SpringWorks Therapeutics Inc (SWTX) Stock Fall in the Biotechnology Field? - InvestorsObserver

Read More...

Does Unity Biotechnology Inc (UBX) Have What it Takes to be in Your Portfolio? – InvestorsObserver

October 13th, 2020 2:59 pm

Unity Biotechnology Inc (UBX) is around the bottom of the Biotechnology industry according to InvestorsObserver. UBX received an overall rating of 35, which means that it scores higher than 35 percent of all stocks. Unity Biotechnology Inc also achieved a score of 23 in the Biotechnology industry, putting it above 23 percent of Biotechnology stocks. Biotechnology is ranked 27 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 35 means the stock is more attractive than 35 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Unity Biotechnology Inc (UBX) stock is trading at $3.95 as of 1:21 PM on Monday, Oct 12, a rise of $0.17, or 4.6% from the previous closing price of $3.78. The stock has traded between $3.81 and $4.15 so far today. Volume today is 893,480 compared to average volume of 976,910.

Click Here to get the full Stock Score Report on Unity Biotechnology Inc (UBX) Stock.

Read more:
Does Unity Biotechnology Inc (UBX) Have What it Takes to be in Your Portfolio? - InvestorsObserver

Read More...

Generex Subsidiary NuGenerex Immuno-Oncology Announces Publication of a Review Article on Cancer Vaccines Highlighting AE37 (Ii-Key-HER2)…

October 13th, 2020 2:59 pm

Exploring Essential Issues for Improving Therapeutic Cancer Vaccine Trial Design

MIRAMAR, Fla., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is happy to announce that a review article on therapeutic cancer vaccines has been published in the peer-reviewed journal Cancers. The paper highlights the importance of proper clinical design in terms of selected groups of patients, taking into consideration (a) changes in initially established standard-of-care treatments; (b) the appropriate follow-up period necessary to achieve meaningful results; (c) statistical considerations for the delay of treatment effects (i.e., time for development of an effective immune response), thus excluding irrelevant early events; and (d) appropriate biomarkers that could guide vaccinations with clinical benefits to patients.

The authors of the paper* have extensive experience with AE37 immunotherapeutic vaccine as principal investigators in the companys breast and prostate cancer trials. The paper clearly describes why the Phase IIb clinical trial of AE37 in breast cancer demonstrated a statistically significant clinical benefit for certain subgroups of patients in the trial (advanced stage disease with low HER2 or triple negative breast cancer) while failing to meet the primary endpoint in the entire intent-to-treat (ITT) study population. The introduction of Herceptin (trastuzumab) as the standard of care during the long-term follow-up of the trial skewed the results such that the benefit of AE37 could not be detected in the statistical analysis. However, when looking at patients in subgroups that did not receive Herceptin, the positive benefits of AE37 on survival become apparent. Patient selection and protocol design that accounts for changes in standard of care are the key to future study designs.

The authors note that the survival benefit with AE37 and other cancer vaccines also require prolonged follow-up because the immune system takes time to activate against the tumor. Therefore, the survival curves only start to diverge after 12 months from treatment initiation. Future trials need to use statistical methods that account for the delayed immune response to exclude early events in order to accurately evaluate the efficacy of immunotherapeutic vaccines.

Further, responders to immunotherapy may be determined using biomarker evaluation, which for AE37 is gamma-interferon, a cytokine secreted by T-cells activated by the Ii-Key vaccine. Those patients who responded to AE37 with strong site reactions and gamma interferon induction demonstrated the most clinical benefit in survival. The use of biomarkers to evaluate cancer vaccine efficacy can significantly improve protocol design and shorten the time from Phase II to Phase III.

This peer-reviewed paper provides further validation of our Ii-Key immunotherapeutic cancer vaccines, said Generex President & CEO Joe Moscato. The recently published results of the AE37 Phase IIb breast cancer trial in over 300 women showed a statistically significant benefit to patients with advanced disease and low HER2 expression, and six of seven AE37 patients with triple negative breast cancer and advanced disease are still alive even after 10 years. As I have said for many years, the introduction of Herceptin as standard of care during the 7-year trial masked the benefit of AE37 in this subgroup, but for those patients who are not eligible for Herceptin therapy, AE37 offers new hope.

Mr. Moscato continued, The paper also validates our future plans for AE37 clinical development, as we plan to initiate a trial in bladder cancer at a preeminent cancer center to evaluate the tumor microenvironment and biomarkers associated with immune system activation by Ii-Key cancer vaccines. As per the authors, and with the help of our scientific and clinical advisory board, we will conduct well-designed clinical trials to support the full potential of AE37 and our other Ii-Key vaccines for cancer and infectious diseases to activate the immune system, and to turn it effectively against a patients tumor.

* The authors Drs. Constantin N. Baxevanis, Sotirios P. Fortis, Alexandros Ardavanis, and Sonia A. Perez of the St. Savas Cancer Hospital in Athens, Greece have previously been investigators for AE37 clinical trials. The company and the authors have no current affiliation.

About NuGenerex Immuno-Oncology

NuGenerex Immuno-Oncology, a public subsidiary of Generex Biotechnology, is a clinical stage oncology company developing immunotherapeutic peptide vaccines based on the CD4 T-Cell activation platform, Ii-Key. NuGenerex Immuno-Oncology (NGIO) has been spun out of Generex as a separate, independent public company to advance the platform Ii-Key technology, particularly in combination with the immune checkpoint inhibitors. NGIO is currently engaged in a Phase II clinical trial of its lead cancer immunotherapeutic vaccine AE37 in combination with pembrolizumab (Mercks Keytruda) for the treatment of triple negative breast cancer.

About Generex Biotechnology Corp.

Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Generex Contact:Generex Biotechnology Corporation

Joseph Moscato646-599-6222

Todd Falls1-800-391-6755 Extension 222investor@generex.com

Original post:
Generex Subsidiary NuGenerex Immuno-Oncology Announces Publication of a Review Article on Cancer Vaccines Highlighting AE37 (Ii-Key-HER2)...

Read More...

Provo-based organization CharityVision sees way to fight blindness – Daily Herald

October 13th, 2020 2:58 pm

October is Blindness Awareness Month, a day set aside to shed light on the importance of vision care and educational outreach. One local organization works year-round to bring awareness, but also to help people around the globe to have healthy vision.

On Saturday, CharityVision, which is based in Provo, celebrated Blindness Awareness Month by holding World Sight Day Art at the The Shops at Riverwoods. The event was open to all community members who wanted to come celebrate sight and the blessings it brings.

Artists were on hand so visitors could watch them create their works. Easels, art supplies and coloring pages were available and people were encouraged to bring their own art projects. The prompt of the day was, Because I see

Our goal is to help people be aware of their vision and the beauty they can see, said Anadine Marshall, CharityVision program director. We want to bring awareness that, all over the world, people struggle with vision.

According to http://www.charityvision.org, Dr. William Jackson, founder, was serving a mission for his church in the Philippines in 1987. While there, he realized that the optimal healthcare solution was not to be found in foreign doctors making medical mission trips. Rather, the solution was with local healthcare professionals.

He organized teams of local professionals who were willing and able to help the vulnerable of their own country who were living with cleft lip, cleft palate, cataracts and club foot. Then called the Deseret International Foundation, it was the beginning of CharityVision.

In the early 2000s, the organization, which is funded largely through donations and some business partnerships, began focusing on eye care.

In just over 30 years, CharityVision has expanded to 26 countries and hundreds of partnerships with local hospitals, doctors and clinics around the globe, it reads on the website.

Doug Jackson, Dr. Jacksons son, now oversees the organization. According to him, CharityVision provided 146,000 surgeries around the world last year alone. Doug Jackson said that the organization helps to provide help to people with all types of vision-related problems. Cataracts are the most commonly treated condition, he said.

When we think of cataracts, we often think of someones vision getting somewhat blurry, but for most of the people that CharityVision helps in other countries, the cataracts have caused complete blindness.

With surgery, they go from blind to sight, Doug Jackson said.

Many of the people we help have nowhere to turn. They cant work, cant go to school, Doug Jackson said. We say, Youre not forgotten.

The organization sends equipment and supplies and at times, sends expeditions to countries. But mostly, support is given to the local doctors and programs in various locations so local people in need are able to get help.

In addition to the international support that CharityVison gives, the organization helps people locally as well. Through the Sight Buddies program, children in Utah County schools are screened. Based on the initial screenings, those who need further screening are able to do that with an eye doctor and can even receive free eyeglasses through the program.

There are 2.2 billion people in the world who dont have access to eyecare who need it, Doug Jackson said. Many have nowhere to turn, they cant work, they cant go to school. We say, Youre not forgotten. When you give somebody their sight back, you give them the world.

See the article here:
Provo-based organization CharityVision sees way to fight blindness - Daily Herald

Read More...

Blindness to cost India Rs 88k crore in 2020: Report – The New Indian Express

October 13th, 2020 2:58 pm

By Express News Service

BENGALURU: The economic burden from vision impairment in India for 2020 amounts to Rs 88,900 crore, and 35% of causes of blindness are preventable and early detection can greatly reduce the economic impact, according to the Status of Child Eye Health in India report published by NGO Orbis which works to prevent and treat vision impairment.

The report, released on World Sight Day, also found that between 2019-20, the loss to gross national income due to blindness in adults would be Rs 9,06,200 crore and Rs 3,31,100 crore for children, for 10 and 40 lost working years, respectively. This includes the loss of economically productive years for both the visually impaired and their care-givers.Many of the conditions that affect children are detectable and treatable, said Dr Rishi Raj Borah, country director at Orbis India. The report brings to light 8-10 conditions in children, which, if diagnosed early, can prevent childhood blindness. These include childhood cataract and glaucoma, he said.

Other factors that affect treatment include availability of doctors. Urban areas have one ophthalmologist for 10,000 people but in rural areas it is one for every 2,50,000. Some children have eye problems at birth, while others develop them by the age of 10. Half of them are detectable and treatable, Dr Borah said.

The shortage of paediatric ophthamologists and paediatric optometrists in India apart, the lack of attention to ophthalmological conditions in primary healthcare also has serious implications for early diagnosis. General physicians and nurses at PHCs may not have the knowledge or time to examine a childs eyes. There is a lack of specialists and sufficient staff at PHCs, and in villages. Anganwadi and ASHA workers also arent trained to detect eye problems, said Dr Parikshit Gogate, paediatric ophthalmologist.

The lack of awareness that blindness can be detected early and even treated combined with stigma associated with it also acts as a preventive factor in seeking help. There is a mindset among parents that younger children do not need spectacles and that only older people suffer from blindness, Dr. Gogate added.Another reason is the lack of public health infrastructure such as specialised equipment, screening mechanism and charts to detect and treat cases. There is also a lack of coordination between gynaecologists, paediatricians and ophthalmologists, the report said.

View post:
Blindness to cost India Rs 88k crore in 2020: Report - The New Indian Express

Read More...

Call for Ideas: Innovative Technology to Reduce Visual Impairment & Blindness – PRNewswire

October 13th, 2020 2:58 pm

BERKELEY, Calif., Oct. 6, 2020 /PRNewswire/ -- Seva Foundation is proud to announce the winners of its 2020 Call For Ideas to identify innovative technology-based solutions to improve eye care delivery. The Berkeley-based vision care humanitarian organization has committed up to $250k to spark innovation in technology to transform lives by restoring sight.

This year's winners are as follows:

Globally, at least 2.2 billion people have a vision impairment, and of these, 1 billion people have a vision impairment that could have been prevented or has yet to be addressed.

"For over four decades, Seva has invested in and used cutting edge technology to deliver world-class care for people in need," says Kate Moynihan, Executive Director of Seva Foundation. "Through our Global Sight Network, these innovations will help us to further extend our reach, and transform more lives than ever before."

"With this support from Seva Foundation, we are excited to explore whether artificial intelligence can be applied to low-cost camera systems," says Dr. Parag Shah of Aravind. "This could help us achieve the goal of eliminating blindness from ROP in India and around the world."

About Seva

Seva is a global nonprofit eye care organization that transforms lives by restoring sight and preventing blindness. Since 1978, Seva has provided sight-saving surgeries, eyeglasses, medicine, and other eye care services to more than 44 million people in underserved communities around the world. We work with partners in more than 20 different countries around the world, including the USA. To find out more, visit http://www.seva.orgor email [emailprotected].

SOURCE Seva Foundation

See the original post:
Call for Ideas: Innovative Technology to Reduce Visual Impairment & Blindness - PRNewswire

Read More...

Shakespeare Theatre announces its 2020-2021 virtual and in person season. – DC Theatre Scene

October 13th, 2020 2:58 pm

Like spring crocuses peeking out of the melting snow, DC-area theaters are beginning to formulate a path back to their audiences, tentative but real. Shakespeare Theatre Company is among the first to do so, with a six-production portfolio not quite a schedule, as dates have not been announced of plays, some virtual, some in person under strict social-distancing protocols, and some both.

On the in person side will be the Donmar Warehouse production of Blindness, an immersive theater production for forty patrons at Harman Hall. Imagine a pandemic which causes blindness and you get the premise of the show, which will be done in darkness. There will be no actors on the stage. The audience will instead hear Juliet Stevensons recorded voice through headphones. Simon Stephens, who adapted The Curious Incident of the Dog in the Night-Time, has put this show together from Jos Saramagos novel.

STC kicks off its digital season, and its STC Digital program, with the world premiere of Patrick Pages one-actor play All The Devils Are Here: How Shakespeare Invented the Villain. Page, himself an expert theatrical villain (he played a memorable Claudius here, and on Broadway has played Scar, the Grinch, the Green Goblin and, in Hadestown, Hades) here takes on the roles of Macbeth, Iago and Claudius (among others) by way of showing us the evolution of Shakespeares villains and our own. While any ticket holder will be able to see the play, STC Season subscribers will have an opportunity for a talkback session with Page.

Juliet Stevenson purrs and seethes in our headphones: as the only sighted survivor, she records turmoil and violence when the afflicted turn against each other, said the Guardian, Ben and Max Ringhams soundscape brilliantly conjures up spaciousness, movement and intimacy. Stevenson seems to prowl around the spectators; a lighter snaps on as if inside our heads. Walter Meierjohann, who directed the show in London, will direct it here.

Tickets for both All The Devils Are Here and Blindness will become available on November 16.

Some time later were not sure when STC will present Ionescos The Chairs. This is a story about an old man and an old woman, setting up chairs so that the whole world, such as it is, can hear a lecture about the old mans discovery. As the audience files in, the old man and the woman speak to them, but the remarkable thing about the audience is that itsinvisible. Or maybe absent. Is this a post-apocalyptic world? Maybe. Is the old mans discovery about the secret of existence? Maybe. Is there actually going to be a speaker? Maybe. Longtime STC Associate Artistic Director Alan Paul directs; this play will be available both in person and digitally.

OK, imagine this. It is 1833, and we are at Londons Royal Theatre. The greatest Shakespearean actor of his time, Edmund Kean, is playing Othello in blackface, of course. Suddenly, Kean collapses on stage! Quick! Bring in the understudy! Butcould this be the understudy? An actual Black actor the American Ira Aldridge? In Lolita Chakrabartis Red Velvet, the response is electric: Britain was full of people theater professionals, critics, and audience alike who thought that by taking the stage Aldridge would bring about the end of civilization. Aldridge, who came to England because he knew he would never get a chance to act in America, responded with personal charisma and a gift for confabulation at one point claiming, falsely, to have been born in Senegal. Chakrabartis play is a fascinating character study of Aldridge, who it sees as an essentially tragic figure, a genius and proto-method actor who was hunted and haunted to his professional end and allowed no personal weakness, said the Chicago Tribunes Chris Jones in a somewhat mixed review. And it serves as a reminder that there is nothing new about our conversations over casting and race. Jade King Carroll directs.

DCTS Guide: The 2020-2021 DC area theatrical season

STC will round out its season with two classics. In Arthur Millers The Crucible, the accusations of hysterical children, led by a manipulative teenager, induce a regional psychosis which results in the deaths of dozens of innocent people. Does this have a contemporary resonance? It certainly did for Miller when he wrote it, and it does for director Whitney White, who directed The Amen Corner B.C. (Before Covid). She has an ambitious plan for this production, says STC Artistic Director Simon Godwin. Whitney is going to revitalize Millers political drama for our times.

And Godwin himself will be helming As You Like It, the Bards magical voyage to the Forest of Arden. You remember As You Like It: The brawling de Boys; ancient Adam; the wrestling match; the Good Duke and the Bad Duke; the forbidden passion of Orlando and Rosalind; love poems posted on trees; melancholy Jacques; all the worlds a stage; girls disguised as boys the whole nine yards. Godwin calls it one of my favorite Shakespearean comedies, an escape from the politics of the court into a green world of wonder, love, and family reunions.

The Chairs, Red Velvet, The Crucible and As You Like It will be available both digitally and in (socially distanced) person.

While individual tickets are not yet available, you can get a season ticket by going here.

Read more from the original source:
Shakespeare Theatre announces its 2020-2021 virtual and in person season. - DC Theatre Scene

Read More...

Thousands denied cure for blindness due to ban on tissue donation from gay men – Washington Blade

October 13th, 2020 2:58 pm

(Photo by Tony Alter; Attribution 2.0 Generic [CC BY 2.0])

A first-of-its-kind medical journal study published on Sept. 24 shows that as many as 3,217 intended donations of corneas from the eyes of gay and bisexual men in 2018 that could have restored the vision of blind people through cornea transplant surgery were disqualified under an outdated U.S. Food and Drug Administration policy aimed at preventing HIV infection.

The study released by JAMA Ophthalmology, an American Medical Association journal, says the little-known FDA policy prohibits the donation of corneas from men who have had sex with men in the past five years from the time of the planned donation. It points out that the policy has not been revised since the FDA adopted it in 1994 despite major scientific advancements in the detection of HIV in human tissue within eight to 10 days after infection.

With millions of people across the world in need of corneal transplants, these discarded corneas from gay and bisexual men could be used to address the shortage and safely restore vision to thousands of patients with corneal blindness or visual impairment, said Dr. Michael A. Puente, assistant professor of ophthalmology at the University of Colorado School of Medicine and lead author of the study.

With modern virologic testing and a better understanding of the low risk of HIV transmission through corneal transplants, this five-year deferral policy for gay men is not supported by current science, Puente, an eye surgeon, said in a statement. We ask federal regulators to reconsider these outdated policies which are depriving patients of the possibility of sight restoration, he said.

Medical literature on cornea donations and corneal transplant surgery states that similar to heart transplants, corneas can only be donated by people who have died, many of whom have left an advance directive to become an organ or tissue donor.

The statement accompanying the study says all corneal donors in the United States are required to undergo three separate HIV tests. Puente told the Washington Blade the HIV tests can be performed shortly before a terminally ill person dies or shortly after death as long as at least one of the tests is performed within seven days of the time the cornea is donated.

Up until 2015, the FDA adhered to a lifetime ban on men who have sex with men, referred to as MSM, from donating blood. The FDA announced that year that a review it conducted concluded that a lifetime ban was no longer scientifically justified and recommended that MSM considering donating blood be sexually abstinent for one year. In April of this year the FDA lowered the period of abstinence for MSM blood donors to three months.

If its safe for gay men to donate their blood after three months of abstinence, I can think of no scientific reason to continue to require gay men to be abstinent for five years to donate their eyes, Puente said. This policy can be changed without increasing the risk of HIV transmission, and I would urge authorities to act as soon as possible to help patients who are waiting for sight-restoring surgery.

The medical journal article says to the knowledge of the teams of researchers who conducted the study, no case of HIV transmission from a corneal transplant has been reported anywhere in the world. The article notes that in cases where a corneal donor was discovered to be HIV positive after a transplant surgery had taken place, none of the recipients contracted HIV.

One reason for the low transmissibility of HIV via corneal transplant is thought to be the corneas avascularity, which prevents the cornea from being a major reservoir of the virus, according to the article. Studies analyzing the corneas of HIV-infected patients have consistently found that that HIV is not present in most of the corneas of HIV-positive patients, it reports.

The statement accompanying the study says the U.S. and Canada are outliers in policies restricting corneal donations for MSM. It notes that Canada currently requires MSM to have been abstinent for one year prior to a corneal donation.

Many countries, including Spain, Italy, Mexico, Chile, and Argentina, allow gay and bisexual men to donate their eye tissue just as easily as heterosexual donors, the statement says. Other countries have deferral periods far shorter than five years, says the statement. For example, the United Kingdom allows corneal donation by gay and bisexual men after only three months of abstinence, while the Netherlands and France only require gay and bisexual corneal donors to be abstinent for four months.

Puente told the Blade he learned that members of Congress urged the FDA to modify its MSM cornea donation policy in 2013 and the Eye Bank Association of America in 2017 also called for a change in the policy, but the FDA chose to leave the 1994 policy in place.

Monique Richards, a spokesperson for the FDA, told the Blade in an email in response to a Blade inquiry about the MSM corneal donor policy, that the current policy is based on recommendations by the U.S. Centers for Disease Control and Preventions 1994 guidelines published in its journal Morbidity and Mortality Weekly Report.

Research has shown that a history of male-to-male sexual contact was associated with a 62-fold increased risk for being HIV positive, whereas the increase in risk for a history of multiple sexual partners of the opposite sex was 2.3 fold, Richards said.

She added that the Centers for Disease Control and Prevention points out that about two-thirds of all new HIV infections in the United states occur in MSM, who make up only 2 percent of the total U.S. population.

The FDA will continue to review its [tissue] donor deferral policies to ensure they reflect the most up-to-date scientific knowledge, Richards said. This process must be data-driven, so the time frame for future changes is not something we can predict.

The JAMA Ophthalmology article can be accessed here.

Read this article:
Thousands denied cure for blindness due to ban on tissue donation from gay men - Washington Blade

Read More...

Second edition of vision quiz is a success – The New Indian Express

October 13th, 2020 2:58 pm

By Express News Service

CHENNAI:The second edition of For Your Eyes Only, a quiz on sight and vision was held on October 8 and October 11, under the auspice of Rajan Eye Care Hospital. This quiz was held as part of World Sight Day, held on the second Thursday of October every year.

World Sight Day aims to focus global attention on vision impairment and blindness. There is a different theme every year, with many of those who mark the day taking the opportunity to both celebrate achievements and advocate for increasing attention towards eye care. Globally, the International Agency for the Prevention of Blindness has a leadership role in preparing the annual World Sight Day.

X QUIZ IT was the knowledge partner and curated the event. The quiz was for schoolchildren from classes 6-12 and the event saw registrations from more than 1,000 students from all across India. On October 8, the preliminary round was held and six students were qualified for the finals that was held on October 11. Tejas Venkataramanan, a student from PSBB School, KK Nagar, was the winner of the quiz. Prateek, a student from Army Public School, Patna, was the runner-up. Sunaina from Army Public School, Nandambakkam, was declared the second runner-up. Gift vouchers amounting to `10,000 and e-certificates will be awarded to top 11 qualifiers. The questions were both informative and appealing, which made the quiz interactive.

In his closing address, Prof Dr Mojan Rajan, chairman and medical director, and a pioneer in cataract surgery, congratulated the participants for their commendable performance and lauded quiz master R Arvind and team X QUIZ IT for their in-depth research, commitment and professionalism.He urged that the message of eye donation should be spread far and wide so that corneal blindness especially among children can be eradicated to a large extent. He also emphasised that eyedonation is a vital humanitarian gesture and a life-enriching gift.

See original here:
Second edition of vision quiz is a success - The New Indian Express

Read More...

India will lose Rs 889 billion in 2020 to blindness: Report – The New Indian Express

October 13th, 2020 2:58 pm

By Express News Service

BENGALURU: The economic burden of blindness in India in 2020 would be Rs 889 billion, stated a report titled 'Status of Child Eye Health in India' published by Orbis, an NGO that works in the prevention and treatment of blindness.

The Cumulative Gross National Income loss due to blindness is Rs 9,062 billion for adults and Rs 3,311 billion for children, for 10 and 40 lost working years, respectively. This can be attributed to the loss of economically productive years not of the visually impaired alone, but that of caregivers as well. The report was released on World Sight Day -- October 8.

Dr. Rishi Raj Borah, Country Director, Orbis India, said, The report brings to light 8 to 10 conditions in children that if diagnosed early can prevent childhood blindness. These include childhood cataract, childhood glaucoma, strabismus (Squint), amblyopia (Lazy Eye), refractive errors, retinopathy of prematurity (ROP) and retinoblastoma."

The report highlights the urban-rural disparity urban areas have 1 ophthalmologist for 10,000 people but in rural areas it is 1 for every 2,50,000 people.

Some eye problems are present at birth, and others develop as the child grows between the age of 0 years to 10 years. Half of them are detectable and treatable and the remaining are not.

Explaining the reasons why early diagnosis of childhood blindness gets missed out in India, Dr. Parikshit Gogate, paediatric ophthalmologist, public health specialist and volunteer faculty at Orbis said, "There is a lack of trained specialists and sufficient manpower at Primary Health Centre and village level. There are not enough paediatric ophthalmologists and paediatric optometrists in the country. Anganwadi and ASHA workers are not trained to detect eye problems. MBBS doctors and nurses at the PHC may not have the knowledge or time to examine the child's eyes."

"There is a mindset among parents that younger children do not need spectacles and they feel wearing one is a sign of weakness. There is a lack of awareness on child blindness as the assumption is that only older people suffer from it. Another reason is the lack of public health infrastructure to detect and treat these conditions in the country," Dr. Gogate added.

Infrastructure includes specialised equipment, screening mechanism and charts for child screening. There is also a lack of coordination between gynaecologists, paediatricians and ophthalmologists, the report finds.

The report also highlights malnutrition, younger children being unable to comprehend that they have a vision problem, genetic factors, global warming and ultraviolet radiation, thermal pollution, heat pollution, water pollution and increased use of digital devices as other reasons for childhood blindness.

The report talks about the interventions that can improve child eye health in India the preventive model, eye screening, building awareness, focus on refractive error, expansion of healthcare, vaccination, Vitamin A supplementation, provision of visual aids etc.

Early detection of 35% of preventable causes of blindness in children can hugely reduce the economic burden of blindness in India, it added.

Read the rest here:
India will lose Rs 889 billion in 2020 to blindness: Report - The New Indian Express

Read More...

International White Cane Day News Of The Area – News Of The Area

October 13th, 2020 2:58 pm

Dale Cleaver, CEO Guide Dogs NSW/ACT.

DEAR News Of The Area,

ON International White Cane Day (15 October), we at Guide Dogs NSW/ACT want to highlight the need for awareness of white canes.

White Cane Day was created to highlight the important role mobility assistance devices play in helping people with low vision or blindness lead safe and independent lives.

This year, our campaign is celebrating the fun, fearless and adventurous spirit of our young Clients and cane users who live life to the fullest, with many engaging in everything from skateboarding to gymnastics.

For many people with low vision and blindness, a white cane is one of the first tools they may learn how to use as part of orientation and mobility training, and for children, a white cane is often the key to their first experiences of independence and freedom. It is a tool they will count on throughout their life.

A white cane is the mobility tool of choice for the majority of Guide Dogs Clients because of its practicality and the way it can give sensory feedback about the surrounding environment, but also its importance as a visual signifier to others in the community of low vision and blindness.

But right now, a white cane is more than a visual symbol that someone has low vision or blindness. It is also a visual symbol that the person using the white cane cant easily maintain a 1.5-metre distance from others.

Weve heard many stories from our Clients who are being increasingly cautious about what environments they travel in with their white cane, aware of the fact that they cant easily see others to socially distance.

This International White Cane Day, we are asking the community to be aware of people using a white cane.

You can help them continue to move safely, confidently and independently through any environment, by giving them 1.5-metres of space.

Id also like to thank everyone who has extended their support to Guide Dogs or our clients, or to anyone who has shown an extra bit of kindness to someone in need this year.

Regards,Dale CLEAVER, CEO Guide Dogs NSW/ACT

Excerpt from:
International White Cane Day News Of The Area - News Of The Area

Read More...

HelpMeSee Launches Revolutionary Technology in Response to the Global Cataract Crisis – PR Newswire India

October 13th, 2020 2:58 pm

"The HelpMeSee team, as well as technology partners Harman, InSimo, and SenseGraphics, are pleased to announce this medical advancement on World Sight Day, an event to advance vision health across the globe," said HelpMeSee President and CEO Saro Jahani. "The HelpMeSee Eye Surgery Simulator overcomes the traditional restraints of cataract surgery training with unlimited virtual practice opportunities. It also offers the benefits of remote simulation-based training during the COVID-19 pandemic, limiting the risks of exposure to coronavirus infection."

More than 60 million people across the world are blind or severely visually impaired simply because they cannot access cataract surgery, according to the World Health Organization (WHO) and the International Association for the Prevention of Blindness (IAPB). The HelpMeSee Simulator and training program along with partners can develop a significant number of cataract specialists that public health experts say are needed to address the developing world ophthalmologist shortage, a factor behind the cataract surgery backlog.

The simulator was the innovative vision of Flight Safety International Founder Albert L. Ueltschi and his son, James "Jim" Tyler Ueltschi. In 2010, they founded HelpMeSee to end the backlog of cataract and visual impairment cases caused by the lack of access to high-quality, affordable cataract surgery.

Jim Ueltschi, Co-Founder and Chairman of HelpMeSee, said, "This achievement will truly change the world of ophthalmology. Every specialist we train on the Eye Surgery Simulator will treat thousands of people each year. Over time, millions will have their vision restored through the cataract surgery skills honed on the HelpMeSee Simulator."

The HelpMeSee Eye Surgery Simulator encompasses an adaptation of an actual virtual microscope used in surgery, two haptic handpieces, a virtual syringe, the patient head and hand rest, and a touchscreen user interface, powerful visuals and simulation software, and everything required to simulate an MSICS surgery. The two handpieces and syringe represent the complete set of surgical instruments needed to perform an MSICS procedure. Programmed lessons with onscreen guides and error messages assist the student in mastering the MSICS technique and the instructor in providing objective feedback.

About HelpMeSee

HelpMeSee is a global not-for-profit campaign to end the backlog of cataract blindness and visual impairment caused by the lack of high quality, affordable cataract surgery. For more information, go to HelpMeSee.org.

MEDIA CONTACT:

Sean Connolly[emailprotected]717-525-3004

Photo - https://mma.prnewswire.com/media/1308699/HelpMeSee.jpg

https://helpmesee.org/

SOURCE HelpMeSee

The rest is here:
HelpMeSee Launches Revolutionary Technology in Response to the Global Cataract Crisis - PR Newswire India

Read More...

Introducing the 2020 AAMC award winners – AAMC

October 13th, 2020 2:58 pm

The developers of a pioneering gene therapy to treat blindness. A health policy expert who was instrumental in the drafting of the Affordable Care Act. A medical school whose commitment to the community extends from creating a COVID-19 clinic for homeless residents to partnering with the local school system to champion careers in health care. These are a few of the recipients of the 2020 AAMC Awards, which recognize individuals and institutions that have made outstanding contributions in medical education, biomedical research, clinical care, and community engagement. The awardees will be recognized during a video tribute in November at Learn Serve Lead 2020: The Virtual Experience.

Sondra Zabar, MD: 2020 Abraham Flexner Award for Distinguished Service to Medical Education

Through scholarship, mentorship, and educational and assessment innovation, Sondra Zabar, MD, professor of medicine at NYU Grossman School of Medicine, has been on the leading edge of teaching and evaluating clinical care. She pioneered the use of unannounced standardized patients to assess trainees clinical performance, and she leads the Standardized Patient Program at NYU/New York Simulation Center, which serves more than 15,000 learners every year. She is a diligent and rigorous scholar, having published more than 70 peer-reviewed articles and authored the seminal textbook on objective structured clinical examinations. She also founded the Program in Medical Education Innovations and Research, which has awarded more than 30 teaching fellowships and 50 seed grants to advance medical education scholarship and institute patient-centered best practices. Dr. Zabars accolades include the Distinguished Teaching Award, NYUs most prestigious educational honor, and the Medical Educator Award and the Scholarship in Medical Education Award from the Society of General Internal Medicine.

Jean Bennett, MD, PhD, and Albert M. Maguire, MD: 2020 Award for Distinguished Research in the Biomedical Sciences

Countless people around the world who were blinded by a once-untreatable disease can now see because of a pioneering gene therapy developed by Jean Bennett, MD, PhD, and Albert M. Maguire, MD, professors of ophthalmology at the Perelman School of Medicine (PSOM) at the University of Pennsylvania. By creating the first gene therapy to treat blindness, Drs. Bennett and Maguire not only reversed the effects of an inherited retinal degenerative disease, Leber congenital amaurosis (LCA), but ignited new research to combat other genetic causes of blindness as well. The therapy, approved by the Food and Drug Administration in 2017 and named Luxturna, replaces a mutated gene, RPE65, that triggers LCA. Drs. Bennett and Maguire continue to lead the development of therapies for impaired vision through their own research and by supporting the work and building the careers of other scientists. They also established the Center for Advanced Retinal and Ocular Therapeutics at PSOM to advance treatments for retinal and ocular diseases through research and training.

Ezekiel J. Zeke Emanuel, MD, PhD: 2020 Robert Wood Johnson Foundation David E. Rogers Award

Few physicians have had as demonstrable an effect on improving the health of Americans in the 21st century as Ezekiel J. Emanuel, MD, PhD, vice provost for global initiatives at the Perelman School of Medicine at the University of Pennsylvania. As special advisor on health policy to the Office of Management and Budget from 2009 to 2011, Dr. Emanuel was instrumental in the drafting and early implementation of the Affordable Care Act, the nations most sweeping health reform law in decades. A renowned bioethicist, Dr. Emanuel has also indelibly shaped clinical research ethics. As founding chair of the Department of Bioethics at the National Institutes of Health for 14 years, Dr. Emanuel led the creation of a training program for bioethicists; initiated the revision of the Common Rule, which brought significant reform to regulations in research involving human subjects; and was integral to crafting the latest Declaration of Helsinki, the World Medical Associations policy statement on medical research involving human subjects.

Cato T. Laurencin, MD, PhD: 2020 Herbert W. Nickens Award

Cato T. Laurencin, MD, PhD, has distinguished himself throughout his 40-year career as a phenomenal physician-scientist and a courageous leader in social justice, equity, and fairness. Through his scholarship and national, regional, and community efforts, he has worked to make a difference in the lives of people affected by racial and ethnic health disparities. Dr. Laurencinco-founded the W. Montague Cobb/National Medical Association Health Institute in Washington, DC, which focuses on addressing health disparities, and he is the founding editor-in-chief of the Journal of Racial and Ethnic Health Disparities. An outstanding administrator and practicing orthopedic surgeon, he previously served as dean of the University of Connecticut (UConn) School of Medicine and vice president of health affairs at UConn. Dr. Laurencin is also an extraordinary scientist whose research has yielded more than 500 publications and patents. He is the first person in history to win both the highest award of the National Academy of Medicine, the Walsh McDermott Medal, and the highest award of the National Academy of Engineering, the Simon Ramo Founders Award. President Obama presented the 2016 National Medal of Technology and Innovation Americas highest award for technological achievement to Dr. Laurencin.

Patricia Garcia, MD, MPH: 2020 Arnold P. Gold Foundation Humanism in Medicine Award

Patricia Garcia, MD, MPH, associate dean for curriculum at Northwestern University Feinberg School of Medicine in Chicago, exemplifies humanism in medicine, working tirelessly to champion her patients, students, and a better society. Attending medical school in the 1980s, Dr. Garcia became intensely interested in caring for patients with HIV and AIDS. As a fellow, she co-founded the first womens HIV program at Northwestern Memorial Hospital. Today, the clinic has a 99% success rate in eliminating maternal-fetal transmission of HIV. She founded the Pediatric AIDS Chicago Prevention Initiative and traveled to labor and delivery units throughout Illinois to train staff in how to perform HIV testing for pregnant mothers and ensure transmission-preventing treatment could be provided. Dr. Garcia is also a big supporter of student-led initiatives, including a recent health care hackathon and the creation of Safe Space Training for faculty and staff, an initiative to improve the learning environment for LGBT+ students.

Rush Medical College of Rush University Medical Center: 2020 Spencer Foreman Award for Outstanding Community Engagement

Established in 1837, Rush Medical College of Rush University Medical Center in Chicago is a trusted service provider and anchor institution where learners, faculty, staff, and administrators continually demonstrate their commitment to the community. At the outset of the COVID-19 pandemic, Rush created the Chicago Homelessness and Health Response Group and Equity (CHHRGE) as an extension of one of the 35 ongoing programs of the Rush Community Service Initiatives Program. Faculty stepped in to provide care for people experiencing homelessness and, working closely with the citys public health officials, CHHRGE continues to administer tests, address outbreaks, provide behavioral health services, and identify gaps in care coordination while laying out a plan for permanent housing. This is just the latest example of the institutions commitment to the health and well-being of its neighbors. Rushs focused recruiting practices leverage community partnerships to provide critical support to job applicants during the hiring process and beyond. Rush is also committed to creating a diverse pipeline of health professionals by working with local students. In particular, Rush has been providing mentoring, tutoring, shadowing, and exposure to health careers to students at the reinvented Richard T. Crane Medical Preparatory High School since 2013.

John W. Bigbee, PhD: 2020 Alpha Omega Alpha Robert J. Glaser Distinguished Teacher Award

Over three decades, John W. Bigbee, PhD, a professor in the Department of Anatomy and Neurobiology at Virginia Commonwealth University School of Medicine, has developed a reputation as an innovative and enthusiastic educator. Throughout his career, he has spent countless hours developing innovative materials and original images to use in teaching students about the microscopic anatomy of tissues. Recognizing changes to educational laboratory environments and the power of technology in the 1990s, Dr. Bigbee and colleague Alice Pakurar, PhD, led an ambitious project to create what he describes as an interactive digital atlas of more than 1,200 histology images and illustrations and associated learning materials. First engineered on CD-ROM in 1998, Digital Histology is now available as an open educational resource for histology learners around the globe. Dr. Bigbees dedication to his learners is also evident from the awards they have bestowed on him, including 27 Outstanding Teaching Awards and the 2002 VCU Award for Innovating Excellence in Teaching, Learning and Technology.

Marianne M. Green, MD, FACP: 2020 Alpha Omega Alpha Robert J. Glaser Distinguished Teacher Award

Since joining the faculty at Northwestern University Feinberg School of Medicine in 1997, Marianne M. Green, MD, FACP, has pioneered educational reform. Under Dr. Greens leadership, Feinberg was among the first medical schools to modernize its curriculum and implement a comprehensive electronic portfolio-based assessment system, which permits the longitudinal measurement of competency achievement and individualized student support for learning.

Dr. Green, who is now senior associate dean for medical education, has led the implementation of several additional curricular innovations at Feinberg. They include implementing the schools first clerkship-associated objective structured clinical examination; designing and implementing an electronic tracking system to better review longitudinal student performance; and designing and implementing competency-based medical education. Currently, Dr. Green is leading a team to implement an entrustable professional activities framework into the competency-based assessment system. She has received more than a dozen teaching awards, including the schools most selective, the George H. Joost Award for Teaching.

Paul A. Hemmer, MD, MPH, MACP: 2020 Alpha Omega Alpha Robert J. Glaser Distinguished Teacher Award

Ever passionate about student and faculty development, Paul A. Hemmer, MD, MPH, MACP, has dedicated his career to improving medical education. As vice chair for educational programs at the Uniformed Services University of the Health Sciences (USUHS) in Bethesda, Maryland, Dr. Hemmer oversees all pre-clerkship educational programs and intradepartmental courses, all medicine clerkship sites in the continental United States and Hawaii, M4 electives throughout the United States, and key faculty development programs and initiatives. Dr. Hemmers associated scholarship in evaluation, curriculum, and faculty development and educational research has also earned him national and international praise. He has received numerous honors, including Academic Grand Master of the U.S. Air Force; the Patil Award for Assessment by the Association for Medical Education in Europe; the Ruth-Marie E. Fincher, MD, Service Award from the Clerkship Directors in Internal Medicine; the Lifetime Achievement Award from the University of Wisconsin-Milwaukee Alumni Association; the Laureate Award from the Air Force Chapter of the American College of Physicians; and the Carol Johns Medal, the highest honor faculty can bestow at the USUHS.

Daniel R. Wolpaw, MD: 2020 Alpha Omega Alpha Robert J. Glaser Distinguished Teacher Award

Over the past four decades, Daniel R. Wolpaw, MD, has been a force for innovation in medical education, envisioning learner development as a complex adaptive challenge aimed at preparing medical students to lead and practice in the health care systems of the future. As professor of medicine and humanities at Penn State College of Medicine in Hershey, Pennsylvania, Dr. Wolpaws notable contributions include developing and co-directing the Systems Navigation Curriculum, developing and co-directing an innovative course in critical thinking, and serving as the design lead for educational innovation at the schools University Park Regional Campus. Before joining Penn State in 2013, Dr. Wolpaw served on the faculty at Case Western Reserve University School of Medicine for 30 years. At both institutions and nationally, he has received high praise for his extraordinary skills as an educator and mentor. His accolades include the Career Achievements in Medical Education Award from the Society of General Internal Medicine and the Newark Beth Israel Healthcare Foundation Humanism in Medicine Award.

For more information about the 2020 awardees, read more here.

Nominations for the 2021 AAMC Awards are now open. Visitaamc.org/awardsto learn more about the criteria and submit a nomination.

Read the original here:
Introducing the 2020 AAMC award winners - AAMC

Read More...

Page 369«..1020..368369370371..380390..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick